Resources
PRI Launches New Center for Medical Economics and Innovation
April 23, 2019
Briefs
SAN FRANCISCO – California-based nonpartisan think tank the Pacific Research Institute today announced the launch of a new Center for Medical Economics and Innovation, which will research and advance policies showing how a thriving biomedical and pharmaceutical sector benefits both patients and economic growth. Timely research, analysis and commentary relating to medical innovation will be available at the new Center’s website - www.medecon.org. “Medical innovation is important to alleviating deadly diseases and helping Americans live long and healthy lives, and it’s also...
U.S. Pneumococcal Vaccination Rates by Ethnicity – 2015
March 27, 2019
Infographics
!function(e,t,s,i){var n="InfogramEmbeds",o=e.getElementsByTagName("script")[0],d=/^http:/.test(e.location)?"http:":"https:";if(/^\/{2}/.test(i)&&(i=d+i),window[n]&&window[n].initialized)window[n].process&&window[n].process();else if(!e.getElementById(s)){var r=e.createElement("script");r.async=1,r.id=s,r.src=i,o.parentNode.insertBefore(r,o)}}(document,0,"infogram-async","https://e.infogram.com/js/dist/embed-loader-min.js");U.S. Pneumococcal Vaccination Rates by Ethnicity - 2015Infogram...
Prescription Drugs % of National Health Expenditures
February 18, 2019
Infographics
!function(e,t,s,i){var n="InfogramEmbeds",o=e.getElementsByTagName("script")[0],d=/^http:/.test(e.location)?"http:":"https:";if(/^\/{2}/.test(i)&&(i=d+i),window[n]&&window[n].initialized)window[n].process&&window[n].process();else if(!e.getElementById(s)){var r=e.createElement("script");r.async=1,r.id=s,r.src=i,o.parentNode.insertBefore(r,o)}}(document,0,"infogram-async","https://e.infogram.com/js/dist/embed-loader-min.js");Infogram...
Novel Drug Approvals by Calendar Year
February 18, 2019
Infographics
!function(e,t,s,i){var n="InfogramEmbeds",o=e.getElementsByTagName("script")[0],d=/^http:/.test(e.location)?"http:":"https:";if(/^\/{2}/.test(i)&&(i=d+i),window[n]&&window[n].initialized)window[n].process&&window[n].process();else if(!e.getElementById(s)){var r=e.createElement("script");r.async=1,r.id=s,r.src=i,o.parentNode.insertBefore(r,o)}}(document,0,"infogram-async","https://e.infogram.com/js/dist/embed-loader-min.js");Novel Drug Approvals per Calendar Year: 2006–2016Infogram...
The Benefits from Repealing the Medical Device Tax
October 18, 2018
Policy Proposals, Studies
The controversial medical device tax hurts doctors, patients and manufacturers and should be repealed by Congress. The medical device tax imposes a 2.3 percent tax on such common items as pacemakers, CT scan machines, dental instruments, and artificial joints. It is currently suspended. Congress isn’t even collecting the revenue it anticipated, and it has also led to lower investment in research and development in new medical technology....
Reforming CMS’ Competitive Bidding Process to Improve Quality and Sustainability
July 18, 2018
Policy Proposals, Studies
Patient health is being negatively impacted by an inefficient system plagued by low provider payments and lack of access to necessary equipment. Proposed reforms to the Medicare competitive bidding process for wheelchairs, home breathing equipment, and other durable medical equipment underscore the findings of this study....
Impediments to a Stronger Biosimilars Market
June 5, 2018
Price and Costs, Studies
By removing barriers holding back the increased use of biosimilars, savings could be significant. In a case study of infliximab, used to treat rheumatoid arthritis, Crohn’s disease, and other illnesses, reforms could realize an annual savings of between $412 million and $465 million....
Promoting Access and Lowering Costs in Health Care: The Case of Empowering Pharmacists to Increase Adult Vaccination Rates
April 17, 2018
Innovation, Studies
Patients could save time and money if federal law is reformed to allow pharmacists to administer all CDC recommended vaccines. Right now, pharmacists are subject to a patchwork of laws in each state that are effectively barriers to vaccines being administered at neighborhood pharmacies. This access barrier exists even though pharmacists receive vaccination training in their pharmacy school education....
Addressing the Problems of Abuse in the 340B Drug Pricing Program
December 13, 2017
Price and Costs, Studies
The 340B program, which was created to give discounted prescription drugs to poor Americans, is riddled with abuse. The program has created a perverse incentive for providers to profit instead of effectively serve the poor and is hurting overall health care quality....
The Economic Costs of Pharmacy Benefit Managers
May 8, 2017
Price and Costs, Studies
This brief explores a tool that millions of Americans use every day when paying for prescription drugs, Pharmacy Benefit Managers, or PBMs, which impact prescription drug costs, access, and patient care. ...
U.S. Pharmaceutical Pricing in Context
April 25, 2017
Price and Costs, Studies
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall and reflect the higher U.S. health care costs compared to the rest of the world....
Nevada proposal to regulate excess costs are price controls by another name
April 24, 2017
Briefs, Price and Costs
De facto price controls will impose heavy costs on Nevada that include higher health care costs and lower health care quality....
Oregon Proposal To Regulate Excess Costs Is Price Controls By Another Name
March 1, 2017
Briefs, Price and Costs
The bill is a creative way to impose price controls, which will impose heavy costs on Oregon, that include higher health care costs, and lower health care quality....
Incenting the Development of Antimicrobial Medicines
Responding to the problem of drug-resistant infections and the decline in the development of new antibiotics, this study explores ways to incentivize the development of new treatments that will effectively address this growing public health crisis....
Improving the Incentive to Innovate
June 22, 2016
Briefs, Innovation
Innovations in the pharmaceutical industry have significantly improved health outcomes for patients and have made important contributions to the U.S. economy. Provisions in the 21st Century Cures bill would help address these problems by accelerating the approval process for innovative pharmaceutical drugs and as a result, extend the effective patent lives for new pharmaceutical innovations....
The Economics of Pharmaceutical Pricing
June 9, 2014
Price and Costs, Studies
The study examines the market forces influencing the often dramatic price differences in pharmaceutical drugs before and after their patents expire....